FDA grants AP status for Lamotrigine ANDA219677 by Taro
The FDA has granted Abbreviated Approval (AP) status for Taro's Lamotrigine ANDA219677.
Published: July 18, 2026
Updated: July 18, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Antiepileptic
Company: Taro
Asset: Lamotrigine
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Taro
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's grant of Abbreviated Approval status for Taro's Lamotrigine marks a significant shift in the competitive landscape of the antiepileptic market. This approval will likely lead to increased competition, impacting pricing strategies and market share for existing products.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor Taro's launch timeline and market uptake of the generic Lamotrigine.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.